Tumor driver gene mutations and wild-type samples used for KM analysis showed better survival outcomes in samples with CSMD1 and ERBB3 wildtype compared to samples with CSMD1 and ERBB3 mutations (Figure 4C). This evidence concerns the gene ERBB3 and neoplasm.